SCHEMBL17825613

SCHEMBL17825613

O=C(O)Nc1cc(Cl)c(Br)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
LMNA P02545 4/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 2/20 0.43
THRA P10827 4/20 0.42
THRB P10828 4/20 0.42
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA5A P35218 1/20 0.41
CA9 Q16790 1/20 0.41
EPHX1 P07099 1/20 0.41
EPHX2 P34913 1/20 0.41
GAA P10253 2/20 0.40
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
P2RY1 P47900 1/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9836435 0.83 MAPT (0.42) MAPTMEN1KMT2ALMNAHTT
SCHEMBL2097418 0.82 THRA (0.44) MAPTMEN1KMT2ALMNAHTT
SCHEMBL7139219 0.81 LMNA (0.52) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1706750 0.80 DHODH (0.54) MAPTMEN1KMT2AHTTNPC1
SCHEMBL27209915 0.79 MAPT (0.41) MAPTMEN1KMT2ALMNAHTT
SCHEMBL23537568 0.78 NPC1 (0.42) MAPTMEN1KMT2ALMNAHTT
SCHEMBL16685574 0.78 KMT2A (0.70) MAPTMEN1KMT2ALMNAHTT
SCHEMBL6864047 0.76 ALDH1A1 (0.41) MAPTMEN1KMT2ALMNAHTT
SCHEMBL3384791 0.75 THRA (0.47) MAPTMEN1KMT2ANPC1THRA
SCHEMBL27209709 0.75 MAPT (0.39) MAPTMEN1KMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3229801-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2020-04-01 EP disclosed
US-10189819-B2 Factor IXa inhibitors MERCK SHARP & DOHME, CORP. (US) 2019-01-29 US disclosed
US-20180030036-A1 Factor IXa Inhibitors MERCK SHARP & DOHME CORP. (US) 2018-02-01 US disclosed
EP-3229801-A1 FACTOR IXA INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-10-18 EP disclosed
WO-2016094260-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030036-A1 Factor IXa Inhibitors F9, TFPI, F12 MAPT 2161/4885MEN1 2982/4885KMT2A 4286/4885
US-10189819-B2 Factor IXa inhibitors F9, TFPI, F12 MAPT 2161/4885MEN1 2982/4885KMT2A 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.